Transparency
Market Research Reports included a detailed market survey and analysis trends
on “Chronic Stable Angina Therapeutics Market”. This report also includes more info about basic
overview of the industry including definitions, applications and global market
industry structure. Angina is a kind of chest pain or discomfort caused by poor
flow of blood in the heart. This often occurs due to narrowing of blood
arteries (atherosclerosis) caused by plaque formation or blood clot.
Browse Full Report with TOC:
People
with obesity, history of heart disease, diabetes, high level of blood
cholesterol and smoking are high risk of getting affected with angina. Some
common symptoms associated with angina include pain, pressure or strange
feeling in chest, shortness of breath, lightheadedness, irregular heartbeat,
nausea or vomiting and weakness. Angina may be of two types: stable angina and
unstable angina. Stable angina is the most common type of angina and is
characterized by predictable pattern of chest pain. On the other hand, unstable
angina has no typical pattern of chest pain. Stable angina happens when the
heart does not get enough oxygen to perform a work which has been asked to do
such as exercise or lifting heavy weight which may also occur due to cold
weather and emotional stress.
Diagnosis
of chronic stable angina includes medical history examination by a doctor and
few tests such as coronary angiography, coronary risk profile (special blood
tests), ECG, exercise tolerance test (stress test or treadmill test), stress
echocardiogram and nuclear medicine (thallium) stress test. The treatment
options for chronic stable angina include lifestyle changes such as daily
exercise and quitting smoking, medications, and procedures such as angioplasty
and stent placement and sometimes heart bypass surgery. Most commonly used
medications include nitrates, ACE inhibitors and calcium channel blockers.
Nicorandil, ranolazine and ivabradine are some of the latest anti-anginal
agents which are also used for treating chronic stable angina.
The
global market for chronic stable angina therapeutics is expected to grow at a
moderate CAGR. Some major factors driving the market growth include high
prevalence of the disease, extensive research and development of new more
effective molecules. According to National Institute for Health and Clinical
Excellence, an estimated 2 million people suffered from with stable angina in
England in 2010. American Heart Association claims that around 9.1 million
people are living with stable angina in the United States. Since stable angina
cannot be cured immediately, it is expected that the base population of
affected people will increase over the years and such high prevalence will
drive market growth particularly in developed countries. The market for chronic
stable angina therapeutics is likely to face significant challenges owing to
patent expiry of major drugs such as bivalirudin (Angiomax/Angiox) in 2015 in
Europe and rosuvastatin (Crestor) in 2016. These patent expiries are expected
to attract generic manufacturers who will intensify the competition by selling
drugs at low prices.
Geographically,
North America represents the largest market, followed by Europe, Asia-Pacific
and Rest of the World. In Asia-Pacific, rapid urbanization leading to life
style changes and emerging economy of key countries such as India and China are
expected to drive the market growth. Obesity, stress and cardiovascular
diseases have become very common and will drive the market in developing
countries significantly. Rapidly evolving medical tourism industry will also play
a key role in driving the market growth in the region as a large number of
people come from foreign countries to countries like India, Indonesia, Thailand
and Singapore for the treatment of chronic stable angina.
There
are many pharmaceutical companies and research institutes which are engaged in
the development, manufacturing and marketing of drugs for treating chronic
stable angina. Some major companies and research institutes include Pfizer,
Inc., Mylan, Inc., Actavis Inc., Chong Kun Dang Pharmaceutical Corp., Roxane
Laboratories, Inc., Gilead Sciences, Inc., CNS, Inc., Nanjing University and
King's College London.
This
research report analyzes this market depending on its market segments, major
geographies, and current market trends. Geographies analyzed under this
research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This
report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming
years
This
report is a complete study of current trends in the market, industry growth
drivers, and restraints. It provides market projections for the coming years.
It includes analysis of recent developments in technology, Porter’s five force
model analysis and detailed profiles of top industry players. The report also
includes a review of micro and macro factors essential for the existing market
players and new entrants along with detailed value chain analysis.
Reasons
for Buying this Report
- This report provides pin-point
analysis for changing competitive dynamics
- It provides a forward looking
perspective on different factors driving or restraining market
growth
- It provides a technological growth
map over time to understand the industry growth rate
- It provides a seven-year forecast
assessed on the basis of how the market is predicted to grow
More Reports On Pharmaceutical Market: -
About Us:-
Transparency
Market Research (TMR) is a market intelligence company providing global
business research reports and consulting services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking insights
for thousands of decision-makers.
Contact Us
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Browse
Market Research Report:-
No comments:
Post a Comment